NCT04717999 is a NA clinical trial of NKG2D CAR-T in Recurrent Glioblastoma, sponsored by UWELL Biopharma.

Who is sponsoring NCT04717999?

NCT04717999 is sponsored by UWELL Biopharma.

What drugs are being tested in NCT04717999?

Interventions in NCT04717999: NKG2D CAR-T.

What condition does NCT04717999 study?

NCT04717999 studies Recurrent Glioblastoma.

Is NCT04717999 still recruiting?

NCT04717999 is currently status unknown. Last updated 22 January 2021.

Last reviewed 2021-01-22 · How we verify

NCT04717999

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pilot Study of NKG2D CAR-T in Treating Patients With Recurrent Glioblastoma

Status unknown NA Last updated 22 January 2021

What this trial tests

NA trial testing NKG2D CAR-T in Recurrent Glioblastoma in 20 participants. Status unknown.

Timeline

1 September 2021

Primary endpoint
30 September 2023

31 December 2023

Quick facts

Lead sponsor	UWELL Biopharma
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	1 September 2021
Primary completion	30 September 2023
Estimated completion	31 December 2023

Drugs / interventions tested

NKG2D CAR-T — full drug profile →

Conditions studied

Recurrent Glioblastoma — all drugs for Recurrent Glioblastoma →

Sponsor

UWELL Biopharma — full company profile →

Who can join

Adults 20 to 70, any sex, with Recurrent Glioblastoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a pilot phase I study to evaluate the safety and efficacy of NKG2D CAR-T cell therapy in patients with relapsed and/or refractory glioblastoma

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives.
Lin H, Liu C, Hu A, Zhang D, et al · · 2024 · cited 232× · PMID 38720342 · DOI 10.1186/s13045-024-01544-7
CAR T cell therapy and the tumor microenvironment: Current challenges and opportunities.
Kankeu Fonkoua LA, Sirpilla O, Sakemura R, Siegler EL, et al · · 2022 · cited 180× · PMID 35434273 · DOI 10.1016/j.omto.2022.03.009
A summary of current NKG2D-based CAR clinical trials.
Curio S, Jonsson G, Marinović S. · · 2021 · cited 63× · PMID 34604863 · DOI 10.1093/immadv/ltab018
Advances in immunotherapy for glioblastoma multiforme.
Mahmoud AB, Ajina R, Aref S, Darwish M, et al · · 2022 · cited 61× · PMID 36311781 · DOI 10.3389/fimmu.2022.944452
CAR T Cell Therapy in Glioblastoma: Overcoming Challenges Related to Antigen Expression.
Luksik AS, Yazigi E, Shah P, Jackson CM. · · 2023 · cited 60× · PMID 36900205 · DOI 10.3390/cancers15051414
Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence.
Kreatsoulas D, Bolyard C, Wu BX, Cam H, et al · · 2022 · cited 53× · PMID 35690784 · DOI 10.1186/s13045-022-01298-0
Regulation of NKG2D Stress Ligands and Its Relevance in Cancer Progression.
Jones AB, Rocco A, Lamb LS, Friedman GK, et al · · 2022 · cited 44× · PMID 35565467 · DOI 10.3390/cancers14092339
CAR-T cell therapy for the treatment of adult high-grade gliomas.
Park S, Maus MV, Choi BD. · · 2024 · cited 38× · PMID 39702579 · DOI 10.1038/s41698-024-00753-0

Verify or expand the search:

Other recruiting trials for Recurrent Glioblastoma

Currently open trials in the same condition.

NCT07480941 — Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma · Phase 1 · recruiting
NCT07209241 — Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM · Phase 1 · recruiting
NCT06910306 — Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma · NA · recruiting
NCT07193628 — B7H3/IL13Ra2 Bispecific Armored Chimeric Antigen Receptor T-Cell Therapy Study for Recurrent/Refractory Glioblastoma · Phase 1 · recruiting
NCT07076472 — Sonodynamic Therapy With SONALA-001 or 5-ALA HCL and Magnetic Resonance Guided Focused Ultrasound for the Treatment of P · EARLY_PHASE1 · recruiting

Other UWELL Biopharma trials

Trials by the same sponsor.

NCT04296461 — Study of Welgenaleucel (UWC19) in Patients With Relapsed or Refractory B-cell Lymphoma · Phase 1 · unknown
NCT03811457 — Immunotherapy With CD19 CAR T-cells in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04717999 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by UWELL Biopharma
Last refreshed: 22 January 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04717999.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing